Tesla’s stock, which has more than quadrupled since last summer, would certainly seem to be in a bubble – and now one model is indicating that, based on the magnitude of Tesla’s price run-up over the trailing two years, there is a more than 80% chance that bubble will burst. For more – including why the odds of a Tesla stock crash may be even worse than this model suggests – CLICK HERE.
While Amazon is the king of online retail, the author of today’s article points to an Achilles heel that threatens its crown – and that has Walmart nipping at the online retail behemoth’s heels. What is Amazon’s Achilles heel, what’s Walmart’s master plan to take advantage of it and charge ahead of its rival, and is buying Walmart stock like buying Amazon stock but at a 73% discount? CLICK HERE.
More than 10 years into this bull market, Buy and Outperform analyst ratings generally come with implied upside potential of 8% to 10%. However, the author of today’s article notes that “One area of the market that can see much greater upside opportunities, which also implies a greater risk, is the biotech and emerging pharmaceutical stocks” – and he proceeds to highlight 20 biotech and pharma stocks that have seen analyst calls since January 1st that suggest much larger upside potential. For more, CLICK HERE.
Investors may be wary of health care stocks heading into an election year where the future of health care in the U.S. will be hotly debated – and drug companies are likely to be the targets of heated rhetoric on both sides. However, Goldman Sachs believes that any changes will be “evolutionary rather than revolutionary” – and its strategists have identified three health care stocks set to outperform next year. For these three stocks, CLICK HERE.
Many articles and books have been written – and movies made – telling stories from the 2008 financial crisis – from those who lost everything to those who made a fortune. However, the author of today’s article states that “there’s an incredible story from 2008 that few people know.” He proceeds to tell that story — about how investors could have made a killing by buying one of the world’s biggest financial companies during the financial crisis — and highlights its lesson for investors about a type of stock that “can deliver huge returns during any kind of market.” CLICK HERE.
Halloween is over and assorted monster costumes have been put away – but there is still monster growth to be had in certain stocks! Today’s article highlights three stocks “with strong monster growth narratives” – each of which has recently reported impressive earnings numbers and had their price targets increased by some of Wall Street’s top-performing analysts as a result. For these three “monster growth” stocks – all of which have “Strong Buy” consensus ratings and upside potential above 20% – CLICK HERE.
Each member of the popular and closely-watched FAANG stocks, as well as Microsoft, reported their most recent quarterly earnings in October – and the gains that followed some solid earnings figures helped propel the S&P 500 to an all-time high. For how each of the FAANG stocks (and Microsoft) performed in quarterly earnings, as well as how much each stock has gained so far this year, CLICK HERE.
The constituents of this S&P 500-beating index, which tracks companies that possess wide economic moats and that are trading at the lowest current market price to fair value, “are a fertile hunting ground for investors looking for high-quality stocks trading at reasonable prices,” advises the author of today’s article. As the index in question is reconstituted regularly, she proceeds to delve into the 15 newest additions to its ranks – as well as the 15 names that were recently removed from the index. For more, CLICK HERE.
The U.S. and China have reached a limited trade deal that will see the Trump Administration suspend a tariff hike on $250 billion worth of Chinese imports and China buy $40 billion to $50 billion in U.S. farm products. With this de-escalation in the protracted trade war, as well as other recent developments such as aggressive pro-stimulus measures announced by various central banks, is it safe for investors to add risk back into their portfolios? For more, CLICK HERE.
You’ve identified and bought a stock that you believe is undervalued. Now, the critical question becomes how long do you wait for that undervalued stock to recover to fair value and reward you? Noting that “the unfortunate truth is that the required timeframe often can or will try the investor’s patience beyond what they can tolerate”, the author of today’s article attempts to establish some expectations – and offers several examples illustrating how undervalued stocks can still reward investors even before recovering to fair value. For more, CLICK HERE.